Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 44.9% in February

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 83,000 shares, an increase of 44.9% from the February 13th total of 57,300 shares. Based on an average trading volume of 318,400 shares, the days-to-cover ratio is currently 0.3 days. Approximately 11.1% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $350.00 price objective on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

Institutional Trading of Windtree Therapeutics

An institutional investor recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics as of its most recent SEC filing. 29.33% of the stock is currently owned by institutional investors.

Windtree Therapeutics Trading Down 6.3 %

Windtree Therapeutics stock opened at $1.92 on Tuesday. The firm has a 50 day simple moving average of $6.72 and a 200 day simple moving average of $44.78. Windtree Therapeutics has a 1-year low of $1.78 and a 1-year high of $737.44. The firm has a market capitalization of $1.44 million, a price-to-earnings ratio of -0.12 and a beta of 0.68.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.